prednisone has been researched along with Bladder Diseases in 5 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We evaluated the efficacy of prednisone in patients with chronic severe IC with Hunner's ulcers unresponsive to first line therapies." | 9.11 | Efficacy of prednisone for severe refractory ulcerative interstitial cystitis. ( Grégoire, M; Soucy, F, 2005) |
| " We evaluated the efficacy of prednisone in patients with chronic severe IC with Hunner's ulcers unresponsive to first line therapies." | 5.11 | Efficacy of prednisone for severe refractory ulcerative interstitial cystitis. ( Grégoire, M; Soucy, F, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Becker, A | 1 |
| Astroza, G | 1 |
| Quezada, N | 1 |
| Riaño, C | 1 |
| Urrutia, J | 1 |
| Guzman, S | 1 |
| Soucy, F | 1 |
| Grégoire, M | 1 |
| Kerr, WS | 1 |
| Gordon, HL | 1 |
| Rossen, RD | 1 |
| Hersh, EM | 1 |
| Yium, JJ | 1 |
| Golimbu, M | 1 |
| Brown, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Controlled Trial Comparing Two Different Bladder Instillation Treatments for Interstitial Cystitis/Bladder Pain Syndrome[NCT03463915] | Phase 3 | 90 participants (Actual) | Interventional | 2019-01-25 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Total scores range: 0-36 (0= no symptoms to 36= the most severe symptoms) (NCT03463915)
Timeframe: Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported
| Intervention | scores on a scale (Mean) |
|---|---|
| Bladder Instillation WITH Triamcinolone Acetonide | -6.7 |
| Bladder Instillation WITHOUT Triamcinolone Acetonide | -5.8 |
VAS is measured on marking on a 10-centimeter (cm) ruler (measured in cm, 0= no pain and 10= most severe pain possible) (NCT03463915)
Timeframe: Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported
| Intervention | score on a scale (Mean) |
|---|---|
| Bladder Instillation WITH Triamcinolone Acetonide | -1.9 |
| Bladder Instillation WITHOUT Triamcinolone Acetonide | -1.8 |
Adverse events will only be those determined to be related to the study drug (NCT03463915)
Timeframe: End of study (6 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Bladder Instillation WITH Triamcinolone Acetonide | 1 |
| Bladder Instillation WITHOUT Triamcinolone Acetonide | 5 |
Total scores range: 0-100 (higher scores on the symptom-severity scale suggestive of greater severity of symptoms and higher scores on the quality-of-life scale suggestive of better quality of life) (NCT03463915)
Timeframe: Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported
| Intervention | score on a scale (Mean) |
|---|---|
| Bladder Instillation WITH Triamcinolone Acetonide | -24.2 |
| Bladder Instillation WITHOUT Triamcinolone Acetonide | -18.8 |
20 question self-administered questionnaire on the presence and absence of pelvic floor symptoms. Score ranges from 0 (least distress) to 300 (most distress). (NCT03463915)
Timeframe: Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported
| Intervention | score on a scale (Mean) |
|---|---|
| Bladder Instillation WITH Triamcinolone Acetonide | -5.3 |
| Bladder Instillation WITHOUT Triamcinolone Acetonide | -6.4 |
Total scores range: 0-35 (0= no symptoms to 35= the most severe symptoms) (NCT03463915)
Timeframe: Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported
| Intervention | score on a scale (Mean) |
|---|---|
| Bladder Instillation WITH Triamcinolone Acetonide | -5.3 |
| Bladder Instillation WITHOUT Triamcinolone Acetonide | -2.7 |
Measures sexual function in women with pelvic floor disorders. Queries about arousal, orgasm, partner-related issues, sexual quality, and desire. The tool also takes into account those who are not sexually active. The questionnaire was used in the study solely to determine if patients had improved dyspareunia (as a categorical variable). (NCT03463915)
Timeframe: Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported
| Intervention | participants (Number) |
|---|---|
| Bladder Instillation WITH Triamcinolone Acetonide | 4 |
| Bladder Instillation WITHOUT Triamcinolone Acetonide | 4 |
1 trial available for prednisone and Bladder Diseases
| Article | Year |
|---|---|
Efficacy of prednisone for severe refractory ulcerative interstitial cystitis.
Topics: Aged; Chronic Disease; Cystitis, Interstitial; Female; Glucocorticoids; Humans; Male; Middle Aged; P | 2005 |
4 other studies available for prednisone and Bladder Diseases
| Article | Year |
|---|---|
[Isolated manifestation of necrotizing vasculitis of the bladder: a case report].
Topics: Anti-Inflammatory Agents; Biopsy; Cyclophosphamide; Cystoscopy; Diagnosis, Differential; Drug Therap | 2008 |
Interstitial cystitis: treatment by transurethral resection.
Topics: Cystitis; Cystoscopy; Dimethyl Sulfoxide; Female; Heparin; Histamine H1 Antagonists; Humans; Menopau | 1971 |
Immunologic aspects of interstitial cystitis.
Topics: Autoantigens; Azathioprine; Biopsy; Coombs Test; Cystitis; Cytotoxicity Tests, Immunologic; Epitheli | 1973 |
Polymyositis with vesical dysfunction.
Topics: Electromyography; Humans; Male; Middle Aged; Muscles; Myositis; Prednisone; Urinary Bladder Diseases | 1973 |